Ocular manifestations of giant cell arteritis

Current Opinion in Ophthalmology

Volumn 9, Issue 6, 1998, Pages 73-79

  Tovilla Canales, Jose L ^a  

^a INSTITUTE OF OPHTHALMOLOGY CONDE DE VALENCIANA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; METHYLPREDNISOLONE; PREDNISOLONE;

CATARACT; CUSHING SYNDROME; DIABETES MELLITUS; DUODENUM ULCER; EARLY DIAGNOSIS; EYE DISEASE; GIANT CELL ARTERITIS; GLAUCOMA; HUMAN; IMMUNE DEFICIENCY; INFECTION; NECROSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC DISEASE;

EID: 0031670678     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199812000-00013     Document Type: Review

References (54)

1. Hayreh SS, Podhajsky PA, Zimmerman B: Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998, 125:509-520.
2. Weyand CM, Bartley GB: Giant cell arteritis: new concepts in pathogenesis and implications for management. Am J Ophthalmol 1997, 123:392-395.
3. Dwolatzky T, Sonnenblick M, Nesher G: Giant cell arteritis and polymyalgia rheumatica: clues to early diagnosis. Geriatrics 1997, 52:38-40.
4. Freeman GA: Urgency in giving steroids in giant cell arteritis is still not widely appreciated [letter]. BJM 1997, 315:549-550.
5. Matteson EL, Gold KN, Bloch DA, Hunder GG: Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification cohort. Am J Med 1996, 100:193-196.
6. Salvarani C, Gabriel SE, O'Fallon M, Hunder GG: The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995, 123:192-194.
7. Hunder GG: Giant cell arteritis and polymyalgia rheumatica. Med Clin North Am 1997, 81:195-219.
8. Weyand CM, Goronzy JJ: The pathogenic role of lymphocytes in vasculitis. Sarcoidosis Vasculitis Diffuse Lung Dis 1996, 13:217-220.
9. Ghanchi FD, Dutton GN: Current concepts in giant cell (temporal) arteritis. Surv Ophthalmol 1997, 42:99-122.
10. Ponte E, Cafagna D: L'arterite gigantocellulare di Horton. Minerva Medica 1997, 88:245-255.
11. Nordborg E, Bengtsson BA, Petursdottir V, Nordborg C: Morphological aspects of giant cell arteritis: an electron-microscopic and immunocytochemical study. Clin Exp Rheumatol 1997, 15:129-34.
12. Weyand CM, Goronzy JJ: Molecular approaches toward pathologic mechanisms in giant cell arteritis and Takayasu's arteritis. Curr Opin Rheumatol 1995, 7:30-36.
13. Weyand CM, Goronzy JJ: Multisystem interactions in the pathogenesis of vasculitis. Curr Opin Rheumatol 1997, 9:3-11.
14. Weyand CM, Schonberger J, Oppitz U, Hunder NH, Hicok KC, Goronzy JJ: Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med 1994, 179:951-960
15. Russo MG, Waxman J, Abdoh AA, Serebro LH: Correlation between infection and the onset of giant cell arteritis syndrome: a trigger mechanism? Arthritis Rheum 1995, 38:374-380.
16. Weynda CM, Tetzlaff N, Bjornsson J, Brack A, Younge B, Goronzy JJ: Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997, 40:19-26.
17. Martinez-Taboada VM, Hunder NN, Hunder GG, Weyand CM, Goronzy JJ: Recognition of tissue-residing antigen by T cells in vasculitic lesions of giant cell arteritis. J Mol Med 1996, 74:695-703.
18. Lavignac C, Jauberteau-Marchan MO, Liozon E, Vidal E, Catanzano G, Liozon F: Etude immunohistochimique des lesions d'e arterite temporale de Horton avant et a ourse de la corticotherapie. Revue Medecine Interne 1996, 17:814-820.
19. Ghanchi FD, Weir C, Dudgeon J: Facial swelling in giant cell (temporal) arteritis. Eye 1996, 10:747-749.
20. Melberg NS, Grand G, Dieckert JP, Barney NP, Blumenkranz MS, Boone DE, Folk JC, Stransky TJ: Cotton-wool spots and the early diagnosis of giant cell arteritis. Ophthalmology 1995, 102:1611-1614.
21. Cid MC, Font C, Oristrelli J, de la Sierra A, Coll-Vinent B, Lopez-Soto A, Vilaseca J, Urbano-Marquez A, Grau JM: Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998, 41:26-32.
22. Desmet GD, Knockaert DC, Bobbaers HJ: Temporal arteritis: the silent presentation and delay in diagnosis. J Intern Med 1990, 227:237-240.
23. Kellner JL: Giant cell arteritis: signs and symptoms. Ophthalmology 1982, 89:1101-1110.
24. Hunder GG, Wyenda CM: Sonography in giant cell arteritis. N Engl J Med 1997, 337:1385-1386.
25. Gur H, Rapman E, Ehrenfeld M, Sidi Y: Clinical manifestations of temporal arteritis: a report from Israel. J Rheumatol 1996, 23:1927-1931.
26. Cornblath WT, Eggenberger ER: Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone. Ophthalmology 1997, 104:854-858.
27. Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG: Visual prognosis in giant cell arteritis. Ophthalmology 1993, 100:550-555.
28. Mizen TR. Giant cell arteritis: diagnostic and therapeutic considerations. Ophthalmol Clin North Am 1991, 4:547-556.
29. Hayreh SS, Podhajsky PA, Zimmerman B: Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol 1998;125:521-526.
30. Finelli PF: Alternating amaurosis fugax and temporal arteritis. Am J Ophthalmol 1997;123:850-851.
31. Galetta SL, Balcer LJ, Liu GT: Giant cell arteritis with unusual flow-related neuro-ophthalmologic manifestations. Neurology 1997, 49:1463-1465.
32. Barricks ME, Traviesa DB, Glaser JS, Levy IS. Ophthalmoplegia in cranial arteritis. Brain 1977, 100:209-21.
33. Schmidt WA, Kraft HE, Vorpahl K, Volker L, Gromnica-Ihle EJ: Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997, 337:1336-1342.
34. Hunder GG, Bloch DA, Michel BA, et al.: The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990, 33:1122-1128.
35. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B: Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997, 123:285-296.
36. Miller A, Green M, Robinson D: Simple rule for calculating normal erythrocyte sedimentation rate. BMJ 1983, 286:266
37. Hanger WA, Sainsbury R, Gilchrist NL, Beard MEJ: Erythrocyte sedimentation rates in the elderly: a community study. N Z Med J 1991, 104:134-136.
38. von Blotzem SG, Borruat FX: Arterite a cellules geantes et vitesse de sedimentation normale: plus que'une exception. Klin Monatsbl Augenheilkd 1996, 208:397-399.
39. Ganchi FD, Williamson TH, Lim CS, Butt Z, Baxter GM, McKillop G, O'Brien C: Colour Doppler imaging in giant cell (temporal) arteritis: serial examination and comparison with non-arteritic anterior ischaemic optic neuropathy. Eye 1996, 10:459-464.
40. Wenkel H, Michelson G: Korrelation der ultraschallbiomikroskopie mit histologischen befunden in der diagnostik der riesenzellarteriitis. Klin Monatsbl Augenheilkd 1997, 210:48-52.
41. Brack A, Rittner HL, Younge BR, Kaltschmidt C, Weyand CM, Goronzy JJ: Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest 1997, 99:2842-2850.
42. Meli B, Landau K, Gloor BP: Die tucken der riesenzellarteriitis aus ophthalmologischer sicht. Schweiz Med Wochenschr 1996, 126:1821-1828.
43. Finlay R: Oral prednisolone 40 mg daily is not adequate for temporal arteritis once vision is affected. BMJ 1997, 315:549.
44. Nesher G, Rubinow A, Sonnenblick M: Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study. Clin Expe Rheumatol 1997, 15:303-306.
45. Matzkin DC, Slamovits TL, Sachs R, Burde RM: Visual recovery in two patients after intravenous methylprednisolone treatment of central retinal artery occlusion secondary to giant cell arteritis. Ophthalmology 1992, 99:68-71.
46. Liu GT, Glaser JS, Schatz NJ, Smith JL: Visual morbidity in giant cell arteritis: clinical characteristics and prognosis for vision. Ophthalmology 1994, 101:1779-1785.
47. Swanell AJ: Polymyalgia rheumatica and temporal arteritis: diagnosis and management. BJM 1997, 314:1329-1332.
48. Roome P: Repeated measurements of erythrocyte sedimentation rate are not efficient use of time or resources [letter]. BJM 1997, 315:550.
49. Salvarani C, Boiardi L, Macchioni P, Rossi F, Tartoni P, Casadei MN, Mancini R, Beltrandi E, Portioli I: Role of peripheral CDB lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 1995, 54:640-644.
50. Font C, Cid MC, Coll-Vinent B, Lopez-Soto A, Grau JM: Clinical features in patients with permanent visual loss due to biopsy proven giant cell arteritis. Br J Rheumatol 1997, 36:251-254.
51. Hayreh SS: Ophthalmic features of giant cell arteritis. Baillieres Clin Rheumatol 1991, 5:431-459.
52. Delecoeuillerie G, Joly P, Cohen deLara AC, Paolaggi JB: Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 survey of 210 patients). Ann Rheum Dis 1988, 47:733-739.
53. Sudlow C: Sensitivity of temporal artery biopsy varies with biopsy length and sectioning strategy. BMJ 1997, 315:549.
54. Wells KK, Folberg R, Goeken JA, Kemp JD: Temporal artery biopsies: correlation of light microscopy and immunofluorescence microscopy. Ophthalmology 1989, 96:1058-1064.